A RANDOMIZED PHASE II STUDY COMPARING CYTARABINE + DAUNORUBICIN (7+3) VS (DAUNORUBICIN AND CYTARABINE) LIPOSOME, CYTARABINE + DAUNORUBICIN + VENETOCLAX, AZACITIDINE + VENETOCLAX, AND (DAUNORUBICIN AND CYTARABINE) LIPOSOME + VENETOCLAX IN PATIENTS AGED …

Last updated:
2026-09-12
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A RANDOMIZED PHASE II STUDY COMPARING CYTARABINE + DAUNORUBICIN (7+3) VS (DAUNORUBICIN AND CYTARABINE) LIPOSOME, CYTARABINE + DAUNORUBICIN + VENETOCLAX, AZACITIDINE + VENETOCLAX, AND (DAUNORUBICIN AND CYTARABINE) LIPOSOME + VENETOCLAX IN PATIENTS AGED 59 OR YOUNGER WHO ARE CONSIDERED HIGH-RISK (ADVERSE) ACUTE MYELOID LEUKEMIA AS DETERMINED BY MYELOMATCH; A MYELOMATCH SUB-STUDY

Intervention/treatment:
VENETOCLAX / AZACITIDINE / DAUNORUBICIN-CYTARABINE
Medical condition:
MYELOID LEUKEMIA
Protocol code:
ALC.8 / MM1YA-S01
Control number:
289634
Status:
No match, ongoing
Approved:
September 13, 2024
Trial phase:
Other
For more information:
DSTS - NCT05554406
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
Accepts healthy volunteers: No

Contacts and locations

Contact
Sponsor
CANADIAN CANCER TRIALS GROUP, CANCER RESEARCH INSTITUTE, QUEEN'S UNIVERSITY

Locations

Alberta

Arthur J E Child Comprehensive Cancer Centre
Calgary, Alberta, T2N 5G2
Recruiting
Name
Site Public Contact
Role
CONTACT
Phone:
888-823-5923
Name
Mary L. Savoie
Role
PRINCIPAL_INVESTIGATOR
University of Alberta Hospital
Edmonton, Alberta, T6G 2B7
Recruiting
Name
Site Public Contact
Role
CONTACT
Phone:
780-407-8798
Name
Joseph M. Brandwein
Role
PRINCIPAL_INVESTIGATOR

Manitoba

CancerCare Manitoba
Winnipeg, Manitoba, R3E 0V9
Recruiting
Name
Site Public Contact
Role
CONTACT
Phone:
866-561-1026
Name
Brett L. Houston
Role
PRINCIPAL_INVESTIGATOR

Nova Scotia

QEII Health Sciences Centre/Nova Scotia Health Authority
Halifax, Nova Scotia, B3H 2Y9
Recruiting
Name
Site Public Contact
Role
CONTACT
Phone:
902-473-6000
Name
Curtis Marcoux
Role
PRINCIPAL_INVESTIGATOR

Ontario

University Health Network-Princess Margaret Hospital
Toronto, Ontario, M5G 2M9
Recruiting
Name
Site Public Contact
Role
CONTACT
Phone:
416-946-4501
Name
Guillaume Richard-Carpentier
Role
PRINCIPAL_INVESTIGATOR

Quebec

CIUSSSEMTL-Hopital Maisonneuve-Rosemont
Montreal, Quebec, H1T 2M4
Recruiting
Name
Site Public Contact
Role
CONTACT
Phone:
514-252-3400
Extension 3329
Name
Julie Bergeron
Role
PRINCIPAL_INVESTIGATOR
CSSS Champlain-Charles Le Moyne
Greenfield Park, Quebec, J4V 2H1
Recruiting
Name
Site Public Contact
Role
CONTACT
Phone:
450-466-5065
Name
Sami Morin-Ben Abdallah
Role
PRINCIPAL_INVESTIGATOR
Jewish General Hospital
Montreal, Quebec, H3T 1E2
Recruiting
Name
Site Public Contact
Role
CONTACT
Phone:
514-340-8222
Extension 8248
Name
Sarit E. Assouline
Role
PRINCIPAL_INVESTIGATOR
Did you find what you were looking for?

Contacts and resources